Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Up 383.3% in January

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 269,200 shares, a growth of 383.3% from the January 15th total of 55,700 shares. Based on an average trading volume of 691,100 shares, the short-interest ratio is currently 0.4 days. Currently, 14.6% of the company’s stock are short sold.

Vincerx Pharma Stock Performance

Shares of NASDAQ VINC opened at $1.25 on Thursday. The stock has a 50 day moving average price of $3.25 and a 200 day moving average price of $8.01. The stock has a market capitalization of $2.80 million, a PE ratio of -0.06 and a beta of 1.37. Vincerx Pharma has a 52 week low of $1.24 and a 52 week high of $187.44.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.